Drug Pricing
Expert articles and analysis related to drug pricing.
AI Summary — Last 30 Days
CMS is pushing drug-pricing reform deeper into managed care operations, with proposals targeting Medicare Advantage provider directory accuracy, PBM transparency, and drug-cost reduction—moves that would increase plan accountability and may reshape MA-PD contracting, formulary strategy, and pharmacy network economics for VBC organizations (AHA summary). At the same time, Medicare market disruption is accelerating: 4.3 million beneficiaries are slated to lose MA drug or stand-alone Part D plans at the end of 2026, creating near-term retention, risk-coding, medication adherence, and care-continuity challenges for ACOs, MA plans, and provider groups managing senior populations (KFF analysis). Medicaid and specialty-drug affordability are also moving toward model-based solutions, with GLP-1 access under the BALANCE Model and the 340B rebate dispute signaling a broader shift from unit-price fights toward budget predictability, pharmacy-channel control, and outcomes-linked access for high-cost therapies.
Related Articles
How Changes in Drug Price Policy Affect Your Wallet and Part D Plan
How Changes in Drug Price Policy Affect Your Wallet and Part D Plan Kiplinger
PBM influence is only growing, American Medical Association report finds
The 10 largest PBMs are also part of a company that owns a health plan.
Brand Drugmakers Raise Median Net Launch Price of New Drugs 35% In Just Three Years
Brand Drugmakers Raise Median Net Launch Price of New Drugs 35% In Just Three Years AHIP
Inside the 340B Rebate Pilot Standoff: Court, Congress, Drugmakers
Administration Finalizes Medicare Part B International Reference Pricing Model
Administration Finalizes Medicare Part B International Reference Pricing Model Health Affairs
Administration Finalizes Medicare Part B International Reference Pricing Model
Administration Finalizes Medicare Part B International Reference Pricing Model Health Affairs
AHA urges court to reject drug industry intervention in 340B rebate program case
AHA urges court to reject drug industry intervention in 340B rebate program case American Hospital Association
Price of new drugs up 35% since 2022: 6 things hospital leaders should know
Price of new drugs up 35% since 2022: 6 things hospital leaders should know Becker's Hospital Review
The U.S. Pays Triple What Other Countries Pay for Drugs. Here’s What the Evidence Says About Fixing It.
The U.S. Pays Triple What Other Countries Pay for Drugs. Here’s What the Evidence Says About Fixing It. AcademyHealth
Analysis finds net launch price for new prescription drugs climbed 35% from 2022 to 2025
Analysis finds net launch price for new prescription drugs climbed 35% from 2022 to 2025 American Hospital Association